Filtered By:
Source: Circulation
Condition: Hypertension
This page shows you your search results in order of date.
Order by Relevance | Date
Total 102 results found since Jan 2013.
Half-Dose Tenecteplase or Primary Percutaneous Coronary Intervention in Older Patients With ST-Segment-Elevation Myocardial Infarction in STREAM-2: A Randomized, Open-Label Trial
CONCLUSIONS: Halving the dose of tenecteplase in a pharmaco-invasive strategy in this early-presenting, older STEMI population was associated with electrocardiographic changes that were at least comparable to those after primary PCI. Similar clinical efficacy and angiographic end points occurred in both treatment groups. The risk of intracranial hemorrhage was higher with half-dose tenecteplase than with primary PCI. If timely PCI is unavailable, this pharmaco-invasive strategy is a reasonable alternative, provided that contraindications to fibrinolysis are observed and excess anticoagulation is avoided.REGISTRATION: URL: ...
Source: Circulation - July 13, 2023 Category: Cardiology Authors: Frans Van de Werf Arsen D Risti ć Oleg V Averkov Alexandra AriasMendoza Yves Lambert Jos é F Kerr Saraiva Pablo Sepulveda Fernando Rosell-Ortiz John K French Ljilja B Musi ć Katleen Vandenberghe Kris Bogaerts Cynthia M Westerhout Alain Pag ès Thierry Source Type: research
Comparison of Unibody and Non-Unibody Endografts for Abdominal Aortic Aneurysm Repair in Medicare Beneficiaries: The SAFE-AAA Study
CONCLUSIONS: In the SAFE-AAA Study, unibody endografts failed to meet noninferiority compared with non-unibody endografts with respect to aortic reintervention, rupture, and mortality. These data support the urgency of instituting a prospective longitudinal surveillance program for monitoring safety events related to aortic stent grafts.PMID:36866664 | DOI:10.1161/CIRCULATIONAHA.122.062123
Source: Circulation - March 3, 2023 Category: Cardiology Authors: Eric A Secemsky Yang Song Tianyu Sun Carmen Gacchina Johnson Megan Gatski Li Wang Andrew Farb Robert E Lee Aurko Shaw Jiaman Xu Robert W Yeh Source Type: research
Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER
CONCLUSIONS: In DAPA-HF and DELIVER, the response to dapagliflozin was similar between men and women. Sex did not modify the treatment effect of dapagliflozin across the range of ejection fraction.PMID:36342789 | DOI:10.1161/CIRCULATIONAHA.122.062832
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Xiaowen Wang Muthiah Vaduganathan Brian L Claggett Sheila M Hegde Maria Pabon Ian J Kulac Orly Vardeny Eileen O'Meara Shelley Zieroth Tzvetana Katova Martina M McGrath Anne-Catherine Pouleur Pardeep S Jhund Akshay S Desai Silvio E Inzucchi Mikhail N Kosib Source Type: research
Mutant Phosphodiesterase 3A Protects From Hypertension-Induced Cardiac Damage
CONCLUSIONS: Although in vascular smooth muscle, PDE3A mutations cause hypertension, they confer protection against hypertension-induced cardiac damage in hearts. Nonselective PDE3A inhibition is a final, short-term option in heart failure treatment to increase cardiac cAMP and improve contractility. Our data argue that mimicking the effect of PDE3A mutations in the heart rather than nonselective PDE3 inhibition is cardioprotective in the long term. Our findings could facilitate the search for new treatments to prevent hypertension-induced cardiac damage.PMID:36259389 | DOI:10.1161/CIRCULATIONAHA.122.060210
Source: Circulation - October 19, 2022 Category: Cardiology Authors: Maria Ercu Michael B M ücke Tamara Pallien Lajos Mark ó Anastasiia Sholokh Carolin Sch ächterle Atakan Aydin Alexa Kidd Stephan Walter Yasmin Esmati Brandon J McMurray Daniella F Lato Daniele Yumi Sunaga-Franze Philip H Dierks Barbara Isabel Montesinos Source Type: research
Leveraging Implementation Science for Cardiovascular Health Equity: A Scientific Statement From the American Heart Association
Circulation. 2022 Oct 10:101161CIR0000000000001096. doi: 10.1161/CIR.0000000000001096. Online ahead of print.ABSTRACTReducing cardiovascular disease disparities will require a concerted, focused effort to better adopt evidence-based interventions, in particular, those that address social determinants of health, in historically marginalized populations (ie, communities excluded on the basis of social identifiers like race, ethnicity, and social class and subject to inequitable distribution of social, economic, physical, and psychological resources). Implementation science is centered around stakeholder engagement and, by vi...
Source: Circulation - October 10, 2022 Category: Cardiology Authors: Nathalie Moise Crystal W Cen é Rachel G Tabak Deborah R Young Katherine T Mills Utibe R Essien Cheryl A M Anderson Francisco Lopez-Jimenez American Heart Association Council on Epidemiology and Prevention; Council on Hypertension; and Stroke Council Source Type: research
